Bristol-Myers Squibb Company

Latest Report Overview

Bristol-Myers Squibb Co (BMY) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $12,973 million with diluted EPS of $1.62 and net income of $3,317 million. Pretax margin was 31.5%, and free cash flow was $3,088 million for the period. Management commentary throughout the filing emphasized strong execution across key growth portfolios, notably in newer product lines offsetting legacy patent losses, while research and development investments remained prioritized at $2,959,000,000 to fuel future pipeline expansion. The company maintained a healthy balance sheet position with cash and cash equivalents of $8,722,000,000 against total debt of $43,120,000,000, reflecting disciplined capital deployment and ongoing debt management strategies.

Key Takeaways for Bristol-Myers Squibb Co

• Bristol-Myers Squibb reported Q2 2026 revenue of $12,973,000,000, up 5.7% year over year, alongside net income of $3,317,000,000 and diluted EPS of $1.62.
• R&D expenditure remained high at $2,959,000,000 for the quarter, highlighting continued aggressive investment in core clinical pipelines across oncology and immunology.
• Free cash flow reached $3,088,000,000 for the period, demonstrating robust cash conversion and disciplined operating efficiency.
• Total debt stood at $43,120,000,000 alongside cash reserves of $8,722,000,000, maintaining manageable leverage metrics relative to operational cash generation.
• Gross margins remained strong at 71.4%, reflecting the premium pricing power inherent in specialized biopharmaceutical treatments.

What Does Bristol-Myers Squibb Co Do?

Bristol-Myers Squibb Co is a global biopharmaceutical company engaged in discovering, developing, licensing, manufacturing, marketing, and distributing innovative medicines. The company's portfolio features leading treatments in oncology, hematology, immunology, and cardiovascular diseases, targeting complex conditions with high unmet medical needs. Key therapeutic categories include advanced immuno-oncology therapies and targeted hematology agents. The company serves a global customer base encompassing healthcare professionals, hospitals, clinics, government health agencies, and managed care providers across North America, Europe, and international emerging markets. Scale indicators include tens of thousands of employees globally, multi-billion-dollar annual revenues, and expansive manufacturing and R&D facilities positioned worldwide. The business model is differentiated by deep scientific expertise, an extensive proprietary patent portfolio, and a high-barrier-to-entry drug discovery engine that translates foundational biological insights into commercialized specialty pharmaceuticals.

Growth Drivers for Bristol-Myers Squibb Co

• Commercial scaling of newly launched oncology and immunology products to replace legacy patent expirations.
• Ongoing label expansion clinical trials unlocking new addressable patient populations for core therapeutic assets.
• Strategic licensing agreements and targeted business development acquisitions integrating external clinical-stage innovations.
• Geographic market expansion and increased international penetration in key emerging healthcare economies.
• Digital and technological integration across clinical trial recruitment and R&D data analytics to accelerate time-to-market.